Cytokinetics, Incorporated
IT ˙ BIT ˙ US23282W6057
62,32 € 0,00 (0,00%)
2026-06-05
DEL PRIS
SecurityIT:1CYTK / Cytokinetics, Incorporated
InstitutionDnB Asset Management AS
Latest Disclosed Ownership12,898 shares
Latest Disclosed Value $ 850,107
DnB Asset Management AS reports 16.42% increase in ownership of 1CYTK / Cytokinetics, Incorporated

On May 14, 2026 - DnB Asset Management AS filed a 13F-HR form disclosing ownership of 12,898 shares of Cytokinetics, Incorporated (IT:1CYTK) valued at $696,492 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 11,079 shares of Cytokinetics, Incorporated. This represents a change in shares of 16.42% during the quarter. The current value of the position is $803,803 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F Cytokinetics COM NEW 23282W605 12,898 1,819 16.42 850 20.91 0.0030
2026-02-05 2025-12-31 13F Cytokinetics COM NEW 23282W605 11,079 869 8.51 704 25.31 0.0025
2025-11-12 2025-09-30 13F Cytokinetics COM NEW 23282W605 10,210 -1,245 -10.87 561 48.41 0.0021
2025-08-12 2025-06-30 13F Cytokinetics COM NEW 23282W605 11,455 1,021 9.79 378 -9.79 0.0016
2025-05-15 2025-03-31 13F Cytokinetics COM NEW 23282W605 10,434 1,221 13.25 419 -3.23 0.0019
2025-02-12 2024-12-31 13F Cytokinetics COM NEW 23282W605 9,213 1,826 24.72 433 11.03 0.0019
2024-11-12 2024-09-30 13F Cytokinetics COM NEW 23282W605 7,387 156 2.16 390 -0.26 0.0018
2024-07-05 2024-06-30 13F Cytokinetics common 23282W605 7,231 645 9.79 392 -15.18 0.0019
2024-04-12 2024-03-31 13F Cytokinetics common 23282W605 6,586 6,586 462 0.0024
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.